Skip to main content
Premium Trial:

Request an Annual Quote

GeneProt Delivers Six Proteins to Partner Novartis

NEW YORK, Dec. 20 - GeneProt has delivered six synthetic proteins to Novartis Pharma as part of the companies' year-old research partnership, GeneProt said on Thursday.


Delivering the synthetic proteins, generated using technology licensed from Gryphon Sciences, marks the first publicly announced transfer of drug candidates to Novartis under the collaboration, signed in October 2000. Of the six proteins, Novartis has selected three for further investigation, the companies said.


One of these is active in modulating the differentiation of cell types, and another is a tachykinin splice variant that has a specific role in the peripheral nervous system. The two companies did not disclose information on the other four proteins. Novartis retains rights to develop all six proteins into therapeutics, diagnostic markers, or drug targets.


"With GeneProt now having demonstrated the ability to provide us with proteomics-based leads on a regular basis, we are looking forward to exciting developments and new pharmaceutical therapies over the coming years," said Jörg Reinhardt, head of development for the Basel, Switzerland-based biotech firm.


In October, GeneProt announced plans to move its corporate headquarters to North Brunswick, NJ, from the Chicago area and build a second proteomics facility near its new headquarters, in addition to the company's flagship facility in Geneva. Novartis is currently GeneProt's only disclosed pharma customer.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.